Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patient

Multiple myeloma (MM) is characterized by the clonal expansion of plasma cells (PC) in the bone marrow (BM). Over the last decade, the outcome of MM patients has substantially improved due to the introduction of several novel anti-MM agents, including proteasome inhibitors (PI: bortezomib (V),